deltatrials
Active Not Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03943173

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions BRCA-Mutated Ovarian Carcinoma BRCA1 Gene Mutation BRCA2 Gene Mutation High Grade Fallopian Tube Serous Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Primary Peritoneal High Grade Serous Adenocarcinoma Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions Chemotherapy Olaparib Therapeutic Conventional Surgery
Updated 18 times since 2019 Last updated: Feb 23, 2026 Started: Jun 7, 2019 Primary completion: Jun 27, 2027 Completion: Jun 27, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates BRCA-Mutated Ovarian Carcinoma and BRCA1 Gene Mutation and is currently ongoing. M.D. Anderson Cancer Center leads this study, which shows 18 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Jan 2020 · 5 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Aug 2023 · 13 months · monthly snapshot~Aug 2023 – ~Dec 2023 · 4 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~May 2025 · 3 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting EARLY_PHASE1

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Feb 2025 — May 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

▶ Show 13 earlier versions

  1. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  3. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Aug 2023 — Dec 2023 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Jul 2022 — Aug 2023 [monthly]

    Recruiting EARLY_PHASE1

  7. Dec 2021 — Jul 2022 [monthly]

    Recruiting EARLY_PHASE1

  8. Jan 2021 — Dec 2021 [monthly]

    Recruiting EARLY_PHASE1

  9. Jul 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

  10. Jan 2020 — Jul 2020 [monthly]

    Recruiting EARLY_PHASE1

  11. Aug 2019 — Jan 2020 [monthly]

    Recruiting EARLY_PHASE1

  12. Jul 2019 — Aug 2019 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Jun 2019 — Jul 2019 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations